Contact Us
Drug Search Results
More Filters [+]

Ipatasertib

Alternative Names: ipatasertib, gdc-0068
Latest Update: 2024-12-11
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: Akt Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Hoffmann-La Roche
Company Location: BASEL SWITZERLAND V8
Company CEO: Severin Schwan
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Ipatasertib

Countries in Clinic: Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Czech Republic, Denmark, Finland, France, Germany, Greece, Hong Kong, Hungary, India, Ireland, Israel, Italy, Japan, Korea, Mexico, New Zealand, North Macedonia, Norway, Peru, Poland, Portugal, Romania, Russia, Singapore, Slovenia, South Africa, Spain, Switzerland, Taiwan, Thailand, Turkey, Ukraine, United Kingdom, United States, Unknown Location

Active Clinical Trial Count: 26

Highest Development Phases

Phase 3: Breast Cancer|Oncology Unspecified|Prostate Cancer|Triple Negative Breast Cancer

Phase 2: Adenocarcinoma|Endometrial Cancer|Endometrioid Carcinoma

Phase 1: Fallopian Tube Cancer|Oncology Solid Tumor Unspecified|Ovarian Cancer|Peritoneal Cancer|Serous Cystadenocarcinoma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
2022-003414-36

P3

Active, not recruiting

Unknown

2033-09-11

jRCT2031230279

P3

Recruiting

Oncology Unspecified

2027-02-28

NCI-2022-07505

P2

Recruiting

Endometrioid Carcinoma|Endometrial Cancer|Adenocarcinoma

2027-01-31

FAIM

P2

Recruiting

Breast Cancer

2026-09-01

Recent News Events

Date

Type

Title

05/01/2024

PubMed

 The highly selective and oral phosphoinositide 3-kinase delta (PI3K-δ) inhibitor roginolisib induces apoptosis in mesothelioma cells and increases immune effector cell composition.

04/03/2024

PubMed

 Proteomic Assessment of SKBR3/HER2+ Breast Cancer Cellular Response to Lapatinib and Investigational Ipatasertib Kinase Inhibitors.

02/28/2024

PubMed

 Effective engineering of a ketoreductase for the biocatalytic synthesis of an ipatasertib precursor.

11/24/2021

News Article

 eFFECTOR Therapeutics Announces Publication of Zotatifin Preclinical Data in Frontiers in Oncology

08/31/2021

News Article

 New Studies Demonstrate the Clinical Application of Predicine's Liquid Biopsy Assay to Detect Gene Copy Number Loss in Patients with Metastatic Prostate Cancer

08/31/2021

News Article

 New Studies Demonstrate the Clinical Application of Predicine's Liquid Biopsy Assay to Detect Gene Copy Number Loss in Patients with Metastatic Prostate Cancer

07/15/2021

News Article

 Prostate Cancer Clinical Landscape Research Report 2021 - ResearchAndMarkets.com

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions